Research And Development
Health
Pharmaceutical

Enzo Biochem

$3.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.31%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Enzo Biochem and other stocks, options, ETFs, and crypto commission-free!

About

Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. Read More The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Employees
503
Headquarters
New York, New York
Founded
1976
Market Cap
152.59M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
182.59K
High Today
$3.29
Low Today
$3.19
Open Price
$3.28
Volume
11.07K
52 Week High
$6.76
52 Week Low
$2.32

Collections

Research And Development
Health
Pharmaceutical
Biotechnology
Medical
Technology

News

Yahoo FinanceMay 10

Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod

NEW YORK--(BUSINESS WIRE)-- Enzo Biochem, Inc. (ENZ) today announced that on May 7, 2019 it was issued U.S. Patent No. 10,278,960 entitled “Sphingosine Pathway Modulating Compounds for the Treatment of Cancers” that is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the compound Ozanimod. Ozanimod is a product of Celgene Corporation (CELG) that is in late-stage clinical development for the treatment of relapsing multiple sclerosis and inflammatory...

346

Earnings

-$0.18
-$0.12
-$0.07
-$0.01
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Jun 10, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.